- Home
- JANX vs PCH Comparison
JANX vs PCH Comparison
Compare JANX & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- PCH
- Stock Information
- Founded
- JANX 2017
- PCH 1903
- Country
- JANX United States
- PCH United States
- Employees
- JANX N/A
- PCH N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- PCH Real Estate Investment Trusts
- Sector
- JANX Health Care
- PCH Real Estate
- Exchange
- JANX Nasdaq
- PCH Nasdaq
- Market Cap
- JANX 1.6B
- PCH N/A
- IPO Year
- JANX 2021
- PCH N/A
- Fundamental
- Price
- JANX $31.05
- PCH $39.08
- Analyst Decision
- JANX Strong Buy
- PCH Strong Buy
- Analyst Count
- JANX 7
- PCH 7
- Target Price
- JANX $94.29
- PCH $48.29
- AVG Volume (30 Days)
- JANX 969.3K
- PCH 521.5K
- Earning Date
- JANX 05-06-2025
- PCH 04-28-2025
- Dividend Yield
- JANX N/A
- PCH 4.61%
- EPS Growth
- JANX N/A
- PCH N/A
- EPS
- JANX N/A
- PCH 0.28
- Revenue
- JANX $10,588,000.00
- PCH $1,062,076,000.00
- Revenue This Year
- JANX N/A
- PCH $1.97
- Revenue Next Year
- JANX $250.58
- PCH $6.19
- P/E Ratio
- JANX N/A
- PCH $141.41
- Revenue Growth
- JANX 30.99
- PCH 3.71
- 52 Week Low
- JANX $22.52
- PCH $36.82
- 52 Week High
- JANX $71.71
- PCH $48.12
- Technical
- Relative Strength Index (RSI)
- JANX 55.36
- PCH 38.83
- Support Level
- JANX $27.93
- PCH $37.87
- Resistance Level
- JANX $32.59
- PCH $40.66
- Average True Range (ATR)
- JANX 1.97
- PCH 1.62
- MACD
- JANX 0.74
- PCH 0.04
- Stochastic Oscillator
- JANX 84.75
- PCH 53.81
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.